You have accessJournal of UrologyProstate Cancer: Advanced1 Apr 2011888 ACCURACY OF FRAX AND GARVAN NOMOGRAMS TO PREDICT OSTEOPOROTIC FRACTURE RISK IN PROSTATE CANCER PATIENTS SUBJECTED TO ANDROGEN SUPRESSION Jacques Planas, Jose Placer, Carles Xavier Raventos, Juan Maria Bastaros, Gloria Encabo, and Juan Morote Jacques PlanasJacques Planas Barcelona, Spain More articles by this author , Jose PlacerJose Placer Barcelona, Spain More articles by this author , Carles Xavier RaventosCarles Xavier Raventos Barcelona, Spain More articles by this author , Juan Maria BastarosJuan Maria Bastaros Barcelona, Spain More articles by this author , Gloria EncaboGloria Encabo Barcelona, Spain More articles by this author , and Juan MoroteJuan Morote Barcelona, Spain More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.754AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Absolute risk assessment of osteoporotic fracture is now recognized as a preferred approach to guide treatment decision. The present study sought to evaluate the behavior of FRAXTM and Garvan nomograms for predicting absolute risk of osteoporotic fractures in prostate cancer (PCa) patients under androgen suppression (AS). METHODS A group of 61 PCa patients under AS with severe osteopenia or osteoporosis (68 to 76 years) were randomized to receive weekly alendronate plus calcium and vitamine D supplements for 12 months (Group 1) versus only supplements (Group 2). Bone mineral density (BMD) at baseline and 12 months was assessed by DXA (Lunar DPX-IQ 4977). Retrospective validation of FRAXTM and Garvan nomograms was done at baseline and 12 months in 43 osteoporotic patients (27 of Group 1 and 16 of Group 2). The 10 years hip fracture risk (10yHFR) and major osteoporotic fracture risk (10yMOFR) were analyzed. RESULTS Mean BMD at femoral neck increased from 0,842 to 0,857 gr/cm2 in Group 1 (p=0,02) and decreased from 0,814 to 0,802 gr/cm2 in Group 2 (p>0,05). In Group 1, 10yHFR decreased from 3,29% to 2,92% in FRAX nomogram (p>0,05) and increased from 9,65% to 9,91% in Garvan nomogram (p>0,05). In Group 2, 10yHFR increased from 3,36% to 3,62% in FRAX nomogram (p>0,05) and from 8,79% to 10,85% in Garvan nomograms (p>0,05). In Group 1, 10yMOFR decreased from 6,04% to 5,63% in FRAXnomogram (p>0,05) and increased from 22,24% to 23,17% in Garvan nomogram (p>0,05). In Group 2, 10yMOFR increased from 6,03% to 6,36% in FRAX nomogram (p>0,05) and from 16% to 17,72% in Garvan nomogram (p>0,05). CONCLUSIONS Alendronate increases BMD in osteoporotic PCA patients under AS and decrease 10yHFR and 10yMOFR according to FRAX nomogram. The behavior of Garvan nomogram does not correlate with BMD changes and its accuracy to predict 10 years fracture risk seems not appropiate in these patients. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e355-e356 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jacques Planas Barcelona, Spain More articles by this author Jose Placer Barcelona, Spain More articles by this author Carles Xavier Raventos Barcelona, Spain More articles by this author Juan Maria Bastaros Barcelona, Spain More articles by this author Gloria Encabo Barcelona, Spain More articles by this author Juan Morote Barcelona, Spain More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...